Article Figures & Data
Tables
Male (n=33) Female (n=9) Mean age 66.2 years 65.8 years Country of Origin East Asian 1 (3%)
Southeast Asia 19 (58%)
South Africa 1 (3%)
Caucasian (Australia) 1 (3%)
Caucasian (USA, Canada) 8 (24%)
Caucasian (Europe) 3 (9%)Southeast Asia 8 (89%)
Southern Asia 1 (11%)Mean dose of systemic minoxidil 4.8 mg (0.06 mg/kg/day) 2.75 mg (0.03 mg/kg/day) Diagnosis of hair disorder Male pattern baldness (100%):
NH classl III (n=3, 9.1%)
NH class III vertex (n=2, 6.1%)
NH class IV (n=4, 12.1%)
NHclass V (n=10, 30.3%)
NH class VI (n=14, 42.4%)Female pattern baldness (78%):
Ludwig II (n=6, 67%)
Ludwig III (n=l, 11%)
Telogen effluvium (n=2, 22%)Mean duration of systemic minoxidil 27.5 months 5.86 months Route of systemic minoxidil Oral 29 8 Sublingual 4 1 Use of other hair loss drugs* F 19 1 S 0 3 K 0 1 TM 1 0 F + TM 4 0 F + D + TM 1 0 F + S + TM + K 1 0 S + K 0 2 K + TM 0 1 No medications other than oral/sublingual minoxidil 7 1 Participants with comorbid conditions Any comorbid conditions 19 (58%) 4 (44%) Hypertension 9 2 Dyslipidemia 7 3 Endocrine disorders Diabetes 4 2 Hypothyroidism 1 0 Cardiac rhythm disorder (Atrial fibrillation, heart block) 2 0 Dermatological disorders (psoriasis) 1 0 Musculoskeletal disorders (Gout) 1 0 Psychiatric/psychological disorders (sleep disorder, depression) 2 0 ↵* F = oral finasteride 1-1.25mg/day, D = oral dutasteride 0.5mg/week, S = spironolactone 25-50mg/day, K = ketoconazole 2% shampoo 2-3 times a week, TM = topical minoxidil 5% foam/solution/lotion
** ARB = angiotensin-receptor blocker, CCB = calcium channel blocker, SARI = serotonin reuptake inhibitor, GLP-1 receptor agonist = glucagon-like peptide-1 receptor agonist, SGLT-2 inhibitor = sodium-glucose co-transporter 2 (SGLT2) inhibitor
Male (n=33) Female (n=9) Total Patients without any AEs 28 (85%) 6 (67%) 34 (81%) Patients with any AEs 5 (15%) 3 (33%) 8 (19%) Adverse events* 5 5 10 Facial or body hypertrichosis 2 (6%) 2 (22%) 4 (9.5%) Upper eyelid swelling 1 (3%) 2 (22%) 3 (7.1%) Palpitations 1 (3%) 1 (11%) 2 (4.8%) Leg swelling 1 (3%) 0 1 (2.4%) ↵* There was more than one adverse event in some participants.
- Table 3.
Routes of Administration, Duration and Presence/Absence of Comorbid Conditions in Patients With and Without Adverse Events (AEs)
Patients Route Duration Comorbid Conditions Oral SL < 6 mos ≥ 6 mos Without With With any AE (n=8) 7 (5-10mg) 1 (5mg) 3 5 3 5 Without AE (n=34) 30 (1-5mg) 4 (5mg) 12 22 15 19 *SL = sublingual
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.